CLINICAL TRIALS PROFILE FOR FORMOTEROL FUMARATE; MOMETASONE FUROATE

All Clinical Trials for FORMOTEROL FUMARATE; MOMETASONE FUROATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00381485 ↗	Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)	Completed	Novartis	Phase 3	2006-07-01	This is a randomized, multicenter, double blind, parallel-group study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) compared with MF MDI 400 mcg BID for 12 weeks. Prior to the 12-week double-blind treatment period, subjects will receive open-label MF MDI 400 mcg BID for 2 to 3 weeks during the run-in period. Efficacy will be measured by the area under the curve from 0 to 12 hours [AUC](0-12 hr) of the change from Baseline to the Week 12 Endpoint in forced expiratory volume in one second (FEV1).
NCT00381485 ↗	Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-07-01	This is a randomized, multicenter, double blind, parallel-group study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) compared with MF MDI 400 mcg BID for 12 weeks. Prior to the 12-week double-blind treatment period, subjects will receive open-label MF MDI 400 mcg BID for 2 to 3 weeks during the run-in period. Efficacy will be measured by the area under the curve from 0 to 12 hours [AUC](0-12 hr) of the change from Baseline to the Week 12 Endpoint in forced expiratory volume in one second (FEV1).
NCT00383240 ↗	Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)	Completed	Novartis	Phase 3	2006-09-01	This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)[MF/F] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, subjects will receive open-label MF MDI 200 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hours) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1) [Time Frame: Baseline to Week 12] and Time-to-First Severe Asthma Exacerbation across the 26-week treatment period.
NCT00383240 ↗	Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2006-09-01	This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)[MF/F] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week double-blind Treatment Period, subjects will receive open-label MF MDI 200 mcg twice daily (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hours) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1) [Time Frame: Baseline to Week 12] and Time-to-First Severe Asthma Exacerbation across the 26-week treatment period.
NCT00383435 ↗	Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)	Completed	Novartis	Phase 3	2006-10-01	This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID and F 10 mcg BID in adults at least 40 years of age, with moderate to severe chronic obstructive pulmonary disease (COPD). All placebo-treated subjects and active-treated subjects who will not participate in the safety extension will be discontinued and will have their Final Visit at Week 26. Subjects who continue into the 26-week safety extension will have their Final Visit at Week 52. Efficacy will be measured by the mean change from Baseline to Week 13 in area under the forced expiratory volume in one second concentration time curve from 0 to 12 hours (FEV1 AUC[0-12hr]) and change from Baseline to Week 13 in AM predose FEV1.

Clinical Trial Conditions for FORMOTEROL FUMARATE; MOMETASONE FUROATE

Condition Name

Condition Name for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Intervention	Trials
Asthma	12
Chronic Obstructive Pulmonary Disease (COPD)	2
COPD	1
Healthy	1

Condition MeSH

Condition MeSH for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Intervention	Trials
Asthma	12
Pulmonary Disease, Chronic Obstructive	3
Lung Diseases, Obstructive	2
Lung Diseases	2

Clinical Trial Locations for FORMOTEROL FUMARATE; MOMETASONE FUROATE

Trials by Country

Trials by Country for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Location	Trials
United States	16
Colombia	2
Latvia	1
Russian Federation	1
Peru	1

Trials by US State

Trials by US State for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Location	Trials
Florida	2
California	2
Wisconsin	1
Virginia	1
Texas	1

Clinical Trial Progress for FORMOTEROL FUMARATE; MOMETASONE FUROATE

Clinical Trial Phase

Clinical Trial Phase for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	9
Phase 2	4

Clinical Trial Status

Clinical Trial Status for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Clinical Trial Phase	Trials
Completed	14
Withdrawn	1

Clinical Trial Sponsors for FORMOTEROL FUMARATE; MOMETASONE FUROATE

Sponsor Name

Sponsor Name for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Sponsor	Trials
Merck Sharp & Dohme Corp.	13
Novartis	8
Schering-Plough	2

Sponsor Type

Sponsor Type for FORMOTEROL FUMARATE; MOMETASONE FUROATE
Sponsor	Trials
Industry	23

Clinical Trials Update, Market Analysis, and Projection for Formoterol Fumarate and Mometasone Furoate

Last updated: October 28, 2025

---

Introduction

The combination of Formoterol Fumarate and Mometasone Furoate represents a pivotal advancement in respiratory pharmacotherapy, notably in managing asthma and chronic obstructive pulmonary disease (COPD). This dual therapy offers targeted bronchodilation alongside anti-inflammatory effects, aligning with the evolving landscape of personalized pulmonary treatment. The current landscape necessitates robust analysis of ongoing clinical trials, market positioning, and future projections to inform stakeholders and guide strategic decision-making.

---

Clinical Trials Overview

Progress and Status

Numerous clinical investigations validate the efficacy and safety profile of combining Formoterol Fumarate, a long-acting beta-agonist (LABA), with Mometasone Furoate, an inhaled corticosteroid (ICS). Notably, several phase III trials are evaluating the formulation’s long-term safety, efficacy, and comparative benefits versus standard therapies.

Key COVID-19 and Non-COVID Respiratory Trials:
Recent trials are predominantly focused on chronic respiratory disease management, emphasizing exacerbation reduction, lung function improvement, and quality of life metrics (1). For example, the KRONOS study demonstrated superior lung function and symptom control with the combination therapy compared to monotherapy across multiple endpoints.

Regulatory Submissions and Approvals:
In the United States and Europe, regulatory agencies (FDA and EMA) are reviewing data supporting marketing authorizations for combination inhalers containing these active pharmaceutical ingredients (APIs). Several formulations by manufacturers like AstraZeneca (e.g., Dulera) have already obtained approval, while others are pending review (2).

Emerging Trials and Future Investigator-led Studies

Upcoming studies aim to investigate:

• The role of Formoterol Fumarate and Mometasone Furoate in specific populations, including elderly and pediatric cohorts.
• A comparative analysis of combination formulations versus single agents.
• The efficacy of novel delivery mechanisms, such as smart inhalers with digital monitoring.

Overall, the ongoing and planned clinical trials underscore a sustained focus on safety, efficacy, and patient-centered outcomes.

---

Market Analysis

Current Market Landscape

The global respiratory inhaler market, valued at approximately $14 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030 (3). The segment featuring ICS/LABA combinations like Formoterol Fumarate and Mometasone Furoate constitutes a significant share, driven by:

• Rising prevalence of asthma and COPD.
• Increasing adoption of inhaled therapies over oral medications.
• Advancements in inhaler device technology.

Key Regional Markets:

• North America: Leading due to high disease prevalence, advanced healthcare infrastructure, and favorable regulatory environment.
• Europe: Significant growth fostered by stringent clinical validation and widespread approval.
• Asia-Pacific: Rapidly expanding owing to increasing healthcare access, urbanization, and disease burden.

Competitive Landscape

Major players include AstraZeneca, Teva Pharmaceuticals, and Glenmark Pharmaceuticals, offering various inhaler formulations. While established products (e.g., Fluticasone Formoterol) dominate current markets, newer formulations with improved bioavailability and patient convenience are gaining traction.

Patent Landscape:
Several patents protecting formulations and delivery systems are nearing expiration, opening avenues for generic and biosimilar entrants. This intensifies price competition and widens accessibility (4).

Market Drivers and Challenges

Drivers:

• Growing global disease burden.
• Rising awareness of inhaler device advantages.
• Enhanced compliance through digital inhalers.

Challenges:

• Patent expirations threatening exclusivity.
• Patient adherence issues.
• Variability in inhaler technique impacting efficacy.

Forecasts and Future Trends

By 2030, the market for ICS/LABA inhalers, including combinations like Formoterol Fumarate and Mometasone Furoate, is anticipated to reach $25-$30 billion. Growth will be fueled by:

• Innovation in inhaler devices (smart inhalers).
• Expansion into pediatric and geriatric segments.
• Integration of digital health solutions for adherence monitoring.
• Increasing prevalence of respiratory diseases, especially in emerging economies.

---

Strategic Market Opportunities

• Developing fixed-dose combinations with improved delivery systems.
• Customizing formulations targeting specific local market needs.
• Collaborating with digital health firms to integrate inhaler use monitoring.
• Navigating patent landscapes to capitalize on opportunities before patent expiration.

---

Regulatory and Commercial Considerations

Regulatory pathways for generic versions are becoming more streamlined, especially with the adoption of biosimilar pathways and real-world evidence data. Manufacturers should focus on demonstrating bioequivalence and safety to accelerate approvals.

Commercially, companies investing in patient education and adherence technology will likely gain competitive advantages, aligning with healthcare shifts toward value-based care models.

---

Conclusion and Future Outlook

The clinical development trajectory and market expansion of Formoterol Fumarate and Mometasone Furoate combinations signal a robust growth phase. As ongoing trials continue to reinforce their efficacy and safety, regulatory approvals are expected to facilitate broader adoption.

Market growth is poised to accelerate, driven by demographic shifts, technological innovations, and strategic patent management. Stakeholders should prioritize innovation, compliance with evolving regulations, and patient-centric solutions to capitalize on emerging opportunities.

---

Key Takeaways

• Regulatory Approvals: Pending and recent approvals underpin the clinical success of Formoterol Fumarate and Mometasone Furoate combinations, with ongoing trials strengthening their evidence base.
• Market Growth: The ICS/LABA segment is projected to grow at a CAGR of 6-8%, reaching up to $30 billion by 2030, with significant contributions from emerging markets.
• Innovation Focus: Advancements in inhaler technology, especially digital and smart inhalers, will enhance patient adherence and therapeutic outcomes.
• Competitive Edge: Companies leveraging patent strategies, device innovation, and digital health integration will secure market share.
• Economic Impact: Increased accessibility through biosimilars and generics will expand treatment reach, especially in low- and middle-income countries.

---

FAQs

1. What are the main clinical benefits of combining Formoterol Fumarate with Mometasone Furoate?
The combination offers superior bronchodilation and anti-inflammatory effects, reducing exacerbations, improving lung function, and enhancing symptom control compared to monotherapy.

2. Are there any notable safety concerns associated with these inhalers?
Clinical trials have demonstrated favorable safety profiles. Potential concerns include systemic corticosteroid effects and beta-agonist side effects, but these are rare when used within prescribed doses.

3. How quickly is the market for these combination inhalers expected to grow?
The market is forecasted to grow at 6-8% CAGR through 2030, driven by increased disease prevalence, technological innovation, and regulatory approvals.

4. What are the main competitive advantages in this market?
Innovative inhaler delivery systems, digital integrations, strong clinical evidence, and strategic patent management confer competitive advantages.

5. What opportunities exist for new entrants into this market?
Opportunities include developing biosimilars, enhancing device technology, targeting underserved populations, and integrating digital health solutions for adherence and outcome monitoring.

---

References

1. ClinicalTrials.gov – Ongoing studies on ICS/LABA combinations.
2. European Medicines Agency (EMA) – Approvals and review status of inhaled corticosteroid/long-acting beta-agonist products.
3. Research and Markets – Global respiratory inhaler market report, 2022.
4. IQVIA – Patent landscape and generic entry implications for respiratory medications.